Shares of BioCryst Pharmaceuticals, Inc. (BCRX) have traded between $1.38 – 9.27. The next earnings date is set for May 13, 2020. Let’s see how its prospects are shaping up.

What does BioCryst Pharmaceuticals, Inc.(BCRX) do?

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.

BCRX Insider Trading Insight

On 2019-11-18, Stonehouse Jon P Pres, CEO purchased 50,000 shares of BCRX. That represents a value of $778,086. Not to be outdone, on 2019-11-18, Sniecinski Megan P – Purchase bought45,000 shares of BCRX. These insiders are clearly in the know because they work closely with the company.

IMGN Intraday Trading

IMGN is due to report earnings on May 01, 2020. In the last year the price has ranged from 1.76 – 7.08. Recently, Enyedy Mark J sold 55,222 shares of IMGN. He is a $83,782 shareholder in IMGN.

Looking for stocks similar to BCRX and IMGN?

Here are some stocks to consider: